PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Oct 31, 2020
Filed with the SEC on Dec 11, 2020 and accepted by EDGAR at Dec 11, 2020, 16:47 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-10-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-08-01 to 2020-10-31 | $0 | us-gaap:Revenues |
| Revenue | 6 months2020-05-01 to 2020-10-31 | $0 | us-gaap:Revenues |
| Research and development | 3 months2020-08-01 to 2020-10-31 | $151.3k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-05-01 to 2020-10-31 | $421.9k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-08-01 to 2020-10-31 | −$949.5k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-05-01 to 2020-10-31 | −$1.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-08-01 to 2020-10-31 | $677 | us-gaap:InterestExpense |
| Interest expense | 6 months2020-05-01 to 2020-10-31 | $1.8k | us-gaap:InterestExpense |
| Net income | 3 months2020-08-01 to 2020-10-31 | −$950.2k | us-gaap:NetIncomeLoss |
| Net income | 6 months2020-05-01 to 2020-10-31 | −$1.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-08-01 to 2020-10-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2020-05-01 to 2020-10-31 | $0.00 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted shares (weighted) | 3 months2020-08-01 to 2020-10-31 | 2,309,218,013 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2020-05-01 to 2020-10-31 | 1,993,895,090 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2020-05-01 to 2020-10-31 | −$1.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2020-10-31 | $3.7m | us-gaap:Cash |
| Current assets | At period end2020-10-31 | $3.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-10-31 | $8.9m | us-gaap:Assets |
| Current liabilities | At period end2020-10-31 | $643.6k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-10-31 | $664.7k | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-10-31 | $8.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001683168-20-004267. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.